On July 13, 2026, the FDA approved Leqembi IQLIK as a subcutaneous starting regimen for early Alzheimer’s disease, replacing the previous IV-only starting choice with a second option: 500 mg injected under the skin once weekly. This made IQLIK the first FDA-approved at-home starting option for Leqembi, but it did not mean patients could immediately begin treatment alone at home. At least the first two consecutive subcutaneous doses require direct guidance from a healthcare provider, and the provider must determine that home administration is appropriate. The approval also did not equal immediate availability.
Eisai said the initiation-dose product was expected to reach U.S. specialty pharmacies in late August 2026. For example, a patient approved for Leqembi in mid-July might still have started with an IV infusion—or waited for pharmacy access—rather than receiving IQLIK at home that month. The new regimen changes how Leqembi can be delivered, not who qualifies or what the treatment is expected to accomplish. Leqembi remains intended for people with confirmed amyloid-beta pathology who are in the mild cognitive impairment or mild dementia stage of Alzheimer’s disease.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Changed for At-Home Leqembi IQLIK Starting Doses After the July 2026 FDA Approval?
- How the 500 mg Weekly IQLIK Starting Regimen Works
- Who Is Eligible for Leqembi After the Label Change?
- Choosing Between Weekly IQLIK Injections and Every-Two-Week IV Infusions
- Safety Monitoring Does Not Become Optional at Home
- What Happens After 18 Months of Treatment?
- What Evidence Supports the Subcutaneous Starting Option?
- Frequently Asked Questions
What Changed for At-Home Leqembi IQLIK Starting Doses After the July 2026 FDA Approval?
Before the July approval, people starting Leqembi received 10 mg/kg by intravenous infusion every two weeks, with each infusion taking about one hour. The revised prescribing information now permits treatment to begin either with that weight-based IV regimen or with a fixed 500 mg subcutaneous IQLIK dose once weekly. This creates a practical comparison between less frequent clinic-based infusions and more frequent injections that may eventually be administered at home. A person using IV Leqembi generally travels to an infusion center every other week.
someone using IQLIK follows a weekly schedule and receives two injections for every 500 mg dose, but may avoid repeated infusion-center visits after completing supervised training. The word “approved” needs careful interpretation. The FDA approved Eisai’s supplemental biologics license application on July 13, while the manufacturer projected specialty-pharmacy availability for late August. Patients and families therefore needed to confirm actual access with the prescribing clinic, insurer, and specialty pharmacy rather than assuming the new regimen was broadly obtainable on the approval date.
How the 500 mg Weekly IQLIK Starting Regimen Works
A 500 mg IQLIK starting dose is not delivered with one 500 mg pen. Each weekly dose consists of two 250 mg/1.25 mL autoinjectors, meaning the patient or caregiver must complete two separate subcutaneous injections to administer the full prescribed dose. That detail matters in everyday care. If a caregiver administers one autoinjector and mistakenly believes the treatment is complete, the patient has received only half of the weekly dose.
Families need clear instructions about injection sites, storage, preparation, device use, disposal, and what to do if a dose is incomplete or an autoinjector does not work as expected. home administration cannot begin solely because a patient or caregiver feels comfortable using an autoinjector. The prescribing information requires a healthcare provider to directly guide at least two consecutive subcutaneous doses and then determine that administration outside a medical setting is appropriate. cognitive impairment, reduced hand strength, poor vision, needle anxiety, unreliable medication routines, or the absence of a dependable caregiver may make supervised or clinic-based dosing safer.
Who Is Eligible for Leqembi After the Label Change?
The July 2026 approval did not expand Leqembi to every person with Alzheimer’s disease. Treatment is initiated in people who have mild cognitive impairment or mild dementia due to Alzheimer’s disease, corresponding to the stages studied in the clinical program. It is not an approved starting treatment for moderate or advanced Alzheimer’s dementia, nor for people with preclinical Alzheimer’s disease who have no cognitive symptoms.
Amyloid-beta pathology must be confirmed before treatment begins. A memory complaint or Alzheimer’s diagnosis by itself is not sufficient. In practice, a patient with mild memory and planning difficulties may undergo an amyloid PET scan or an appropriate cerebrospinal-fluid assessment before the clinical team decides whether Leqembi is an option. This distinction can prevent a misleading interpretation of “at-home Alzheimer’s treatment.” IQLIK is not a general injection that can be prescribed based only on forgetfulness, and it does not replace the diagnostic evaluation, baseline safety assessment, MRI planning, or ongoing specialist oversight associated with anti-amyloid therapy.
Choosing Between Weekly IQLIK Injections and Every-Two-Week IV Infusions
The main tradeoff is convenience versus dosing frequency and administration responsibility. IV initiation requires a 10 mg/kg infusion approximately every two weeks, usually in a medical facility, while IQLIK initiation uses a fixed 500 mg subcutaneous dose every week. IV treatment involves travel, scheduling, venous access, and about an hour of infusion time; home IQLIK shifts more of the weekly routine to the patient or caregiver after supervised instruction. Consider a patient who lives 90 minutes from the nearest infusion center. Weekly home injections could reduce travel considerably once the clinical team authorizes them, but the household would need to manage two autoinjectors each week and maintain an accurate dosing calendar.
For a patient living close to an infusion clinic who has no reliable caregiver, the every-two-week IV schedule may remain more manageable despite the appointments. The label also permits switching between routes during starting treatment. A patient moving from IV to subcutaneous dosing begins IQLIK one week after the last IV dose. A patient moving from subcutaneous treatment to IV receives the infusion no sooner than two weeks and no later than three weeks after the last IQLIK dose. These intervals should be scheduled by the treatment team rather than improvised at home.
Safety Monitoring Does Not Become Optional at Home
Changing the injection setting does not remove the major safety concerns associated with lecanemab. Leqembi carries a boxed warning for amyloid-related imaging abnormalities, commonly called ARIA, which can involve brain swelling or bleeding. Some cases are asymptomatic, while others can produce headache, confusion, dizziness, vision changes, nausea, weakness, difficulty walking, seizures, or other neurological symptoms. Home dosing can make it easier to confuse convenience with lower medical risk.
A caregiver should not respond to new neurological symptoms by simply delaying the next injection or changing the schedule without contacting the treating team. Severe or sudden symptoms require urgent medical evaluation, and treatment decisions may depend on examination and brain imaging. Patients still need the MRI monitoring and clinical follow-up specified for Leqembi, even when injections occur outside an infusion center. Risk assessment is particularly important when considering factors such as APOE ε4 status and medications that affect clotting. The supervised first doses teach device use, but two successful injections do not eliminate the need for continued neurological monitoring.
What Happens After 18 Months of Treatment?
After 18 months, patients may continue their existing starting regimen or transition to maintenance dosing. Maintenance choices include IV Leqembi at 10 mg/kg every four weeks or subcutaneous IQLIK at 360 mg once weekly. The 360 mg weekly maintenance option was approved in August 2025; the July 2026 action added the subcutaneous initiation regimen.
For example, a patient could receive 500 mg of IQLIK weekly during the initial 18 months and then move to 360 mg weekly for maintenance. Another patient might begin with IV treatment every two weeks and later use monthly IV maintenance. Route switching is allowed during maintenance as well, but the timing should follow the prescribing information and the clinician’s dosing plan.
What Evidence Supports the Subcutaneous Starting Option?
The established clinical-benefit evidence comes from the IV regimen studied in Clarity AD, also identified as Study 2. Among 1,795 participants, IV lecanemab at 10 mg/kg every two weeks produced an 18-month difference of −0.45 points on the Clinical Dementia Rating–Sum of Boxes compared with placebo, representing 27% less decline.
The subcutaneous formulation was not evaluated in a separate, large clinical-outcome trial designed to independently demonstrate reduced cognitive and functional decline. The new route was approved using the broader Leqembi evidence package rather than a second Clarity AD-sized outcomes study of weekly home injections. That limitation is important when discussing the evidence: the delivery option is new, while the principal demonstration of clinical benefit remains based on IV lecanemab.
Frequently Asked Questions
Was at-home Leqembi IQLIK available immediately after the July 13, 2026 approval?
Not broadly. July 13 was the FDA approval date, while Eisai said the initiation-dose product was expected to become available through specialty pharmacies in late August 2026.
Can a patient take the first IQLIK dose alone at home?
No. A healthcare provider must directly guide at least two consecutive subcutaneous doses and determine that home administration is appropriate before the patient or caregiver self-administers.
Is the 500 mg weekly dose one injection?
No. One 500 mg starting dose requires two 250 mg/1.25 mL autoinjectors and therefore two injections.
Did the approval make Leqembi available for later-stage Alzheimer’s disease?
No. Treatment remains initiated in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, and amyloid-beta pathology must be confirmed first.
Can someone switch between IV Leqembi and IQLIK?
Yes. During initiation, IV-to-subcutaneous treatment begins one week after the last IV dose. Subcutaneous-to-IV treatment is scheduled two to three weeks after the last subcutaneous dose.
Was weekly subcutaneous IQLIK tested in its own large clinical-outcome trial?
No. The main evidence for slowing cognitive and functional decline comes from the 1,795-participant Clarity AD study of IV lecanemab.
